Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Study of NPT200-11 in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02606682
Recruitment Status : Completed
First Posted : November 17, 2015
Last Update Posted : February 15, 2016
Sponsor:
Collaborator:
UCB S.A. - Pharma Sector
Information provided by (Responsible Party):
Neuropore Therapies Inc.

Brief Summary:
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered NPT200-11 in healthy subjects. In addition, the maximally tolerated dose will be determined.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: NPT200-11 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Single Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT200-11 in Healthy Subjects
Study Start Date : July 2015
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NPT200-11 - Cohort 1, Dose 1
Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
Drug: NPT200-11
Single doses of NPT200-11capsules, orally administered

Drug: Placebo
Single doses of microcrystalline cellulose capsules, orally administered
Other Name: Microcrystalline cellulose capsules

Experimental: NPT200-11 - Cohort 2, Dose 2
Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
Drug: NPT200-11
Single doses of NPT200-11capsules, orally administered

Drug: Placebo
Single doses of microcrystalline cellulose capsules, orally administered
Other Name: Microcrystalline cellulose capsules

Experimental: NPT200-11 - Cohort 3, Dose 3
Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
Drug: NPT200-11
Single doses of NPT200-11capsules, orally administered

Drug: Placebo
Single doses of microcrystalline cellulose capsules, orally administered
Other Name: Microcrystalline cellulose capsules

Experimental: NPT200-11 - Cohort 4, Dose 4
Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
Drug: NPT200-11
Single doses of NPT200-11capsules, orally administered

Drug: Placebo
Single doses of microcrystalline cellulose capsules, orally administered
Other Name: Microcrystalline cellulose capsules

Experimental: NPT200-11 - Cohort 5 ,Dose 5
Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
Drug: NPT200-11
Single doses of NPT200-11capsules, orally administered

Drug: Placebo
Single doses of microcrystalline cellulose capsules, orally administered
Other Name: Microcrystalline cellulose capsules

Experimental: NPT200-11 -Cohort 6, Dose 6
Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
Drug: NPT200-11
Single doses of NPT200-11capsules, orally administered

Drug: Placebo
Single doses of microcrystalline cellulose capsules, orally administered
Other Name: Microcrystalline cellulose capsules

Experimental: NPT200-11 - Cohort 7, Dose 7
Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
Drug: NPT200-11
Single doses of NPT200-11capsules, orally administered

Drug: Placebo
Single doses of microcrystalline cellulose capsules, orally administered
Other Name: Microcrystalline cellulose capsules




Primary Outcome Measures :
  1. Safety, including adverse events, physical examinations, ECGs, clinical laboratory tests [ Time Frame: Screening (28 days prior to dosing) through Day 7 ]
    Safety, as determined by the number of participants with adverse events related to treatment, the number of participants with clinically significant changes in blood pressure, heart rate and respiration, the number of participants with abnormal laboratory values, the number of participants with abnormal ECGs.


Secondary Outcome Measures :
  1. To possibly determine the maximally tolerated dose (MTD) of orally administered NPT200-11 in healthy subjects. [ Time Frame: Screening (28 days prior to dosing) through Day 7 of MTD ]
    The number of participants with unacceptable toxicities at each dose level will determine the maximally tolerated dose.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects who meet all of the following inclusion criteria will be eligible to participate in this study:

  1. informed of, and willing and able to comply with, all of the protocol requirements and the investigational nature of the study, and have signed an informed consent form in accordance with institutional and regulatory guidelines;
  2. male or female adults between 18 and 55 years of age, inclusive;
  3. female subjects must be post-menopausal for at least 2 years or surgically sterile (hysterectomy, bilateral oophorectomy, tubal ligation);
  4. male subjects must be willing to use an adequate barrier method of contraception for the duration of the study and for 90 days after dosing and no sperm donations for the duration of the study and for 90 days after dosing. Male subjects who are surgically sterile need not employ a method of contraception;
  5. non-smokers for at least six months;
  6. BMI = 18 - 30 kg/m2, inclusive;
  7. in good health, in the judgment of the Principal Investigator, as determined by:

    • medical history indicative of no serious or severe chronic conditions requiring frequent medical intervention or continual pharmacologic management, and no medical or social conditions that would potentially interfere with the subject's ability to comply with the study visit schedule or the study assessments;
    • no clinically significant abnormalities in body temperature, heart rate, respiratory rate, blood pressure;
    • no clinically significant abnormalities in the 12-lead electrocardiogram (ECG);
    • no clinically significant abnormalities in clinical chemistry (ALT, AST, total bilirubin must be at or below the upper limit of normal and eGFR must be above 90 mL/min), hematology (hemoglobin ≥ 12.0 g/dL), coagulation and urinalysis; lab tests may be repeated, if necessary (details are provided in the attached flow chart of study assessments).
  8. negative results on the following screening laboratory tests: urine drug screen, urine alcohol screen, serum pregnancy test, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus antibody.

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria will NOT be eligible to participate in this study:

  • females of child bearing potential;
  • history of a significant medical condition that may interfere with absorption, distribution or elimination of NPT200-11, or with the clinical and laboratory safety assessments in this study;
  • history of drug hypersensitivity and disorders affecting respiratory function (e.g., COPD, asthma) and cardiac disorders predisposing to cardiac adverse events;
  • history of or current alcohol abuse and/or other drug addiction < 2 years prior to screening, or a positive urine drug or alcohol screen (e.g., amphetamines, barbiturates, benzodiazepines, opiates, cannabinoids, alcohol and cocaine);
  • positive for HBVsAg, HCV Ab, HIV Ab;
  • 12 lead ECG showing the following: having a corrected QTc interval > 450 msec or <320 msec (Fridericia's correction);
  • sustained sitting systolic blood pressure > 140 or < 90 mm Hg or sitting diastolic blood pressure > 90 or < 50 mm Hg at Screening or Day -1 (sentinel pair) or Day 1 (remaining 6 subjects in the cohort), the average of the 2 assessments of BP taken at each visit will be used to exclude a subject;
  • resting pulse rate at screening of > 100 or < 45;
  • donated or lost > 500 mL of blood < 56 days prior to enrollment into this study;
  • plasma donation within 7 days prior to enrollment into this study;
  • active infection or febrile illness < 14 days prior to the first dose of study medication;
  • use of prescription or over-the-counter medications or herbal supplements ≤ 14 days prior to dosing and until completion of follow-up visit on Day 7;
  • have participated in other clinical studies of a new chemical entity within 30 days prior to admission to the CRU.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02606682


Locations
Layout table for location information
United States, Arizona
Celerion, Inc
Tempe, Arizona, United States, 85283
Sponsors and Collaborators
Neuropore Therapies Inc.
UCB S.A. - Pharma Sector
Investigators
Layout table for investigator information
Principal Investigator: Danielle Armas, M.D. CPI Celerion

Layout table for additonal information
Responsible Party: Neuropore Therapies Inc.
ClinicalTrials.gov Identifier: NCT02606682     History of Changes
Other Study ID Numbers: NPT200-11-001
First Posted: November 17, 2015    Key Record Dates
Last Update Posted: February 15, 2016
Last Verified: November 2015
Keywords provided by Neuropore Therapies Inc.:
Phase 1
Safety
Tolerability
Pharmacokinetics
Parkinson's Disease